Sign up to get updates from us
Turning a biological process on or off is like flipping a light switch. However, these approaches often come with serious side effects that can limit therapeutic utility. For this reason, treating certain types of CNS disorders like chronic pain, PTSD, and cognitive impairment requires a more nuanced modulatory approach to restore normal brain function. Listen in as Aptinyx’s newly minted president & CEO Andy Kidd, MD explains how the company is taking a novel approach to NMDA receptor modulation to help create a platform of small molecules aimed at restoring normal brain balance to address a host of serious neurological disorders.
